Zacks Rank and Stock Performance - The Zacks Rank system has a strong track record, with 1 stocks generating an average annual return of +25% since 1988 [1] - Pfizer currently holds a Zacks Rank of 2 (Buy) [1] - Pfizer's stock closed at $26 56, marking a -0 67% move from the previous day, underperforming the S&P 500's daily loss of 0 04% [2] - Over the past month, Pfizer's shares appreciated by 3 52%, outperforming the Medical sector's loss of 4 31% and the S&P 500's gain of 1 05% [2] Earnings and Revenue Projections - Pfizer's upcoming earnings per share (EPS) are projected to be $0 48, reflecting a 380% increase from the same quarter last year [3] - Revenue for the upcoming quarter is anticipated to be $17 48 billion, indicating a 22 67% upward movement from the same quarter last year [3] - For the full year, earnings are projected at $2 91 per share, representing a +58 15% change from the prior year [4] - Full-year revenue is estimated at $63 34 billion, reflecting an +8 28% change from the prior year [4] Valuation Metrics - Pfizer is currently traded at a Forward P/E ratio of 9 18, marking a discount compared to its industry's average Forward P/E of 13 9 [9] - Pfizer has a PEG ratio of 0 65, significantly lower than the Large Cap Pharmaceuticals industry average PEG ratio of 1 46 [11] Industry and Analyst Insights - The Large Cap Pharmaceuticals industry has a Zacks Industry Rank of 136, placing it in the bottom 46% of all 250+ industries [10] - Analyst estimate revisions for Pfizer reflect the latest short-term business trends and can indicate confidence in the company's performance [5] - Research shows that estimate alterations are directly linked with near-future stock price performance [6]

Core Insights - High-yield dividend stocks attract investors due to their potential for substantial current income and long-term appreciation [1] Group 1: Pfizer - Pfizer's ability to maintain and grow its dividend is stronger than its payout ratio suggests, with management confident in raising the dividend despite near-term pressures from transitioning beyond COVID-19 revenue [3][5] - Pfizer's recent dividend increase to $0.43 per share marks its 345th consecutive quarterly payment, reflecting strong financial performance and commitment to returning value to shareholders [5] - The company currently yields 6.53%, significantly above the large-cap pharmaceutical-peer average of 4.2%, with a payout ratio of 221%, indicating it pays more in dividends than it earns [9][12] Group 2: Altria - Altria, the largest U.S. tobacco company, has a dividend yield of 7.58%, exceeding the tobacco peer average of 6.7%, supported by a manageable payout ratio of 67.3% [6][14] - The company is transitioning into alternative products, with a $2.75 billion acquisition of NJOY, while maintaining a strong market share with its Marlboro brand, which commands over 40% of the U.S. cigarette market [4][13] - Despite declining cigarette volumes, Altria's pricing power allows for continued price increases to offset volume declines, making it a more favorable option for income-focused investors compared to Pfizer [7][14]

Pfizer hosted a discussion with sell-side analysts to provide an update on one of the vaccine pipeline items – a second-generation Clostridioides difficile (C. diff) vaccine effort in Phase 2.Goldman Sachs analyst Chris Shibutani maintained a Buy rating on Pfizer, Inc PFE with a price target of $33.Shibutani recalled that Pfizer had reported negative results from a Phase 3 study for a first-generation asset in March 2022, where the primary endpoint was unmet.Also Read: Elon Musk’s xAI To Expand With New Cha ...

As an investor in Pfizer (NYSE: PFE ), one of the world's largest pharmaceutical companies, I am marginally disappointed, as other investors would be, that the company had another underwhelming year on the stock markets.Uttam is a growth-oriented investment analyst whose equity research primarily focuses on the technology sector. Semiconductors, Artificial Intelligence and Cloud software are some of the key sectors that are regularly researched and published by him. His research also focuses on other areas ...

Stuart Therapeutics adds recognized leaders in ophthalmology therapeutics development, commercialization.STUART, Fla., Dec. 22, 2024 /PRNewswire/ -- Stuart Therapeutics announced today the appointment of Tracy Valorie and Jason Werner to the company's Board of Directors, bringing the total number of Board members to five. These new Directors will hold the positions previously held by Robert O. Baratta, MD, who passed away suddenly in the third quarter of this year, and retired US Representative Diane Black, ...

Amid a fall season characterized by restive shareholders seeking an activist bid to unseat senior management and change the trajectory of the company, Pfizer (PFE 2.29%) is communicating that everything is under control. Per its updated forecast for its 2024 and 2025 fiscal years on Dec. 17, the overarching message is that the pharma will continue to seek to control its costs while bolstering its portfolio of medicines as usual.But does that make the stock a buy, or is there reason to be cautious? Let's dig ...

In the latest market close, Pfizer (PFE) reached $25.77, with a -0.46% movement compared to the previous day. This change lagged the S&P 500's 0.09% loss on the day. Meanwhile, the Dow experienced a rise of 0.04%, and the technology-dominated Nasdaq saw a decrease of 0.1%.The the stock of drugmaker has risen by 3.81% in the past month, leading the Medical sector's loss of 2.1% and the S&P 500's loss of 0.29%.Analysts and investors alike will be keeping a close eye on the performance of Pfizer in its upcomin ...

Shares of Pfizer (PFE -2.04%) recently marched higher in response to a dividend payout raise and a forward-looking presentation. Management confirmed the annual revenue and earnings outlook it provided in October and issued guidance for the year ahead.In response to Pfizer's latest guidance update, BMO Capital analyst Evan Seigerman reiterated an outperform rating and a $36 per-share price target. If Pfizer stock reaches Seigerman's target, investors who buy at recent prices could see their principal invest ...

The major pharmaceutical maker Pfizer Inc. (NYSE: PFE ) recently reported its 2025 guidance on December 17 th, so I thought I would take another look at PFE from the technical analysis approach. My most recent article aboutAs an individual investor nearing retirement I am trying to build my financial assets in order to have a fulfilling retirement. I am interested in trading both long and short; or at least using inverse ETFs, to take advantage of market declines. Having long term and short term trading str ...

Core Viewpoint - Pfizer's stock rose nearly 5% following the announcement of its 2025 revenue guidance, projecting total revenues between $61.0 billion and $64.0 billion, which aligns with investor expectations [1][2]. Financial Guidance - For 2025, Pfizer expects total revenues of $61.0 to $64.0 billion and adjusted earnings between $2.80 and $3.00 per share, with the Zacks Consensus Estimate at $62.86 billion and $2.90 per share respectively [1][2]. - The 2024 financial guidance remains unchanged, with total revenues projected in the same range as 2025 and adjusted earnings expected between $2.75 and $2.95 per share [2]. Revenue and Earnings Projections - Excluding COVID product revenues, Pfizer anticipates a 9% to 11% operational revenue increase in 2024 [2]. - The adjusted earnings guidance for 2025 indicates a year-over-year operational growth of 10% to 18% from the midpoint of 2024 guidance [6]. Cost Management and Savings - Pfizer achieved $4 billion in savings through cost cuts and restructuring in 2024, with an additional $500 million expected in 2025 [8]. Market Position and Product Performance - Despite a decline in COVID-related revenues, Pfizer's non-COVID operational revenues improved in the first three quarters of 2024, driven by key products like Vyndaqel and Eliquis, as well as new launches and acquisitions [9]. - The acquisition of Seagen has strengthened Pfizer's oncology position, contributing $2.3 billion in sales in the first nine months of 2024, a 38% increase on a proforma basis [10]. Challenges Ahead - Pfizer faces challenges from declining sales of COVID-19 products and anticipates significant impacts from patent expirations between 2026 and 2030 [11].